Figure S9 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy

2026 Open access

Read full text
Authors: Myriam Ben Khelil, Maxime Fredon, Nawfel Adib, Adeline Bouard, Marie Perchaud, Syrine Abdeljaoued, Charles-Frédéric Mantion, Kamal Asgarov, Philippe Guillaume, Laurie Spehner, Evan Seffar, Marjorie Labesse
+13 more Angélique Vienot, Virginie Mougey, Mathieu Gonçalves-Venturelli, Sara Bobisse, Alexandre Harari, Camilla Jandus, Francine Garnache‐Ottou, Delphine Binda, Olivier Adotévi, Yann Godet, Marie Kroemer, Christophe Borg, Romain Loyon
DOI: 10.1158/2326-6066.31024178
Cited by: 0

Abstract

SALL4-TCR T cells exhibit anti-tumor activity in vivo.

Fields of Study & Subjects

Renal and related cancers CAR-T cell therapy research Acute Lymphoblastic Leukemia research

Publication details

Publication date
8 January 2026